Proto Labs (PRLB) CFO acquires 20,686 shares at reported $0 price

Rhea-AI Filing Summary

Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported acquiring additional company stock. On January 29, 2026, he acquired 20,686 shares of Proto Labs common stock at a reported price of $0 per share. Following this transaction, he directly beneficially owned 47,645 shares of Proto Labs common stock, as disclosed in this Form 4 insider filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schumacher Daniel

(Last) (First) (Middle)

5540 PIONEER CREEK DRIVE

(Street)

MAPLE PLAIN MN 55359

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Proto Labs Inc [ PRLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		A		20,686	A	$0	47,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ W. Morgan Burns, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Proto Labs (PRLB) disclose in this Form 4?

Proto Labs disclosed that its Chief Financial Officer, Daniel Schumacher, acquired 20,686 shares of Proto Labs common stock. The transaction occurred on January 29, 2026 and was reported on a Form 4 insider filing with the U.S. Securities and Exchange Commission.

How many Proto Labs (PRLB) shares does the CFO hold after the reported transaction?

After the reported transaction, Chief Financial Officer Daniel Schumacher beneficially owned 47,645 shares of Proto Labs common stock. This total reflects his direct holdings following the acquisition of 20,686 shares disclosed in the Form 4 filing dated January 29, 2026.

At what price per share did the Proto Labs (PRLB) CFO acquire the reported shares?

The Form 4 shows that the 20,686 shares of Proto Labs common stock were acquired at a reported price of $0.00 per share. This zero-dollar price typically indicates a non-cash acquisition, as reflected in the transaction price column of the filing.

Who is the reporting person in this Proto Labs (PRLB) Form 4 filing?

The reporting person is Daniel Schumacher, the Chief Financial Officer of Proto Labs Inc. The Form 4 identifies him as an officer of the company and reports changes in his beneficial ownership of Proto Labs common stock as of January 29, 2026.

What type of security is involved in the Proto Labs (PRLB) insider transaction?

The insider transaction involves Common Stock of Proto Labs Inc. The Form 4 specifies this as the title of the non-derivative security for which 20,686 shares were acquired and a total of 47,645 shares were owned directly after the transaction.

Is the Proto Labs (PRLB) CFO’s ownership reported as direct or indirect in this Form 4?

The Form 4 reports Chief Financial Officer Daniel Schumacher’s beneficial ownership of Proto Labs common stock as direct (D). The table shows 47,645 shares held directly after the acquisition, with no additional nature of indirect beneficial ownership disclosed in the provided data.